← Back to screener

Aurinia Pharmaceuticals Inc. AUPH

Rank #2215 · Nasdaq · $2.1B market cap
Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.
Score
29.0
P/E
-27.4
P/B
5.28
ROE
-19.2%
Op. Margin
-52.2%
Debt Ratio
43%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -27.4x, P/B 5.28x. Ranks in the top 71% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -19.2%. Ranks in the top 84% of the universe.

Safety ★★★★☆
Good

Debt ratio 43%. Ranks in the top 21% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★☆
Excellent

Revenue growth of 31.0% year over year. Ranks in the top 12% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2020$0.0B$-0.1B$-0.1B$0.2B-11930.914
2021$0.0B$-0.1B$-0.1B$0.1B-28598.441
2022$0.1B$-0.1B$-0.1B$0.3B-208.122
2023$0.0B$-0.2B$-0.2B$0.4B-396.316
2024$0.1B$-0.1B$-0.1B$0.5B-83.236
2025$0.2B$-0.1B$-0.1B$0.4B-52.243

← See the full screener